SINGAPORE, July 10, 2019-- One BioMed Pte Ltd, a Singapore-based medical diagnostics company, announced today that it has closed a US$5 million Series A financing round, led by Singapore-based Biopath Ventures and US-based ARCH Venture Partners, with Enterprise Singapore's investment arm, SEEDS Capital, also participating. The company, a spin-off of A*STAR in 2016, is developing leading-edge platform technologies for diagnostics testing.